Literature DB >> 23340893

Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines.

Jamie R Wood1, Kellee M Miller, David M Maahs, Roy W Beck, Linda A DiMeglio, Ingrid M Libman, Maryanne Quinn, William V Tamborlane, Stephanie E Woerner.   

Abstract

OBJECTIVE: To assess the proportion of youth with type 1 diabetes under the care of pediatric endocrinologists in the United States meeting targets for HbA1c, blood pressure (BP), BMI, and lipids. RESEARCH DESIGN AND METHODS: Data were evaluated for 13,316 participants in the T1D Exchange clinic registry younger than 20 years old with type 1 diabetes for ≥1 year.
RESULTS: American Diabetes Association HbA1c targets of <8.5% for those younger than 6 years, <8.0% for those 6 to younger than 13 years old, and <7.5% for those 13 to younger than 20 years old were met by 64, 43, and 21% of participants, respectively. The majority met targets for BP and lipids, and two-thirds met the BMI goal of <85th percentile.
CONCLUSIONS: Most children with type 1 diabetes have HbA1c values above target levels. Achieving American Diabetes Association goals remains a significant challenge for the majority of youth in the T1D Exchange registry.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23340893      PMCID: PMC3687259          DOI: 10.2337/dc12-1959

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


The Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study have demonstrated in adolescents and adults that intensive diabetes management significantly reduces the risk of vascular complications in type 1 diabetes (1,2) and that this benefit is sustained over time (3). In addition to glucose control, hypertension, dyslipidemia, and obesity (4–7) increase risk for future vascular disease, and these risk factors can be present in youth with type 1 diabetes. Both the American Diabetes Association (ADA) (8–10) and the International Society for Pediatric and Adolescent Diabetes (ISPAD) (11) have established targets for HbA1c, blood pressure (BP), lipids, and BMI for youth with type 1 diabetes. The T1D Exchange clinic registry provides an opportunity to assess the frequencies of youth meeting these targets.

RESEARCH DESIGN AND METHODS

The T1D Exchange Clinic Network includes 67 United States–based pediatric or adult endocrinology practices. A registry of individuals with type 1 diabetes commenced enrollment in September 2010 (12). Each clinic received approval from an institutional review board (IRB). Informed consent was obtained according to IRB requirements from adult participants and parents or guardians of minors, and assent was obtained from minors. This report includes 13,316 participants from 67 sites enrolled through 1 August 2012, who were younger than 20 years old at enrollment with type 1 diabetes for >1 year. Data were collected for the registry’s database from the participant’s medical record and by having the participant or parent complete a comprehensive questionnaire (12). A recent HbA1c value (within 6 months before enrollment) was available for 99% (N = 13,226) of participants (82% obtained using DCA, 3% from another point-of-care device, 12% from a laboratory, 3% by an unrecorded method). Data for BP and BMI were available for 12,664 (95%) and 13,045 (98%) participants. Among the 12,639 participants age 6 years or older, fasting LDL, HDL, and fasting triglycerides were available for 2,928 (23%), 8,693 (69%), and 2,387 (19%) participants, respectively (lipid results are not reported for participants age 1 to younger than 6 years because of the small amount of data). Data were categorized according to the following ADA and ISPAD targets: HbA1c (ADA <8.5% for those younger than 6 years of age, <8.0% for those 6 to younger than 13 years of age, and <7.5% for those 13 to younger than 20 years of age; ISPAD ≤7.5% for all ages); BP <90th percentile for age, sex, and height; BMI <85th percentile for age and sex; LDL <100 mg/dL (<2.6 mmol/L); HDL (ADA >35 mg/dL; ISPAD >1.1 mmol/L); and triglycerides <150 mg/dL (<1.7 mmol/L). The proportion of participants meeting ISPAD and ADA targets for HbA1c, BP, lipids, and BMI were tabulated according to age group. Differences in the characteristics of participants meeting HbA1c targets were evaluated through logistic regression models adjusted for potential confounders. In view of the large sample size, only P < 0.01 was considered statistically significant.

RESULTS

Among the 13,316 pediatric participants, 677 (5%) were 1 to younger than 6 years of age, 5,336 (40%) were 6 to younger than 13 years of age, and 7,303 (55%) were 13 to younger than 20 years of age (mean age, 12.7 years; mean diabetes duration, 5.6 years; 48% female; 78% non-Hispanic white). An insulin pump was used by 55% of participants and a continuous glucose monitor was used by 3%. The median (25th and 75th percentile) number of self-reported self-monitoring of blood glucose per day was 5 (4,7). The ISPAD and ADA targets for HbA1c, BP, BMI, and lipids are shown according to age in Fig. 1. Mean ± SD for HbA1c was 8.2 ± 1.1% in those 1 to younger than 6 years old, 8.3 ± 1.2% in those 6 to younger than 13 years old, and 8.8 ±1.7% in those 13 to younger than 20 years old. The age-specific ADA HbA1c target was met by 32% of participants and the ISPAD HbA1c target of ≤7.5% was met by 25% of participants. The percentage meeting ADA and ISPAD HbA1c targets was higher in the younger age groups compared with the group 13 to younger than 20 years old (P < 0.001 for ADA and ISPAD). Among pump users 1 to younger than 6 years old, the proportions of participants meeting the ADA and ISPAD HbA1c targets were 79 and 37% compared with 50 and 17% among injection users (P < 0.001, adjusted for diabetes duration, race/ethnicity, household income, insurance, and self-monitoring of blood glucose per day). In those 6 to younger than 13 years old, 50 and 32% of insulin pump users met the ADA and ISPAD HbA1c targets compared with 34 and 20% of injection users (P < 0.001). There was not a significant difference in the percentage meeting HbA1c targets between insulin pump users and injection users among the group 13 to younger than 20 years old (24 and 27% of pump users vs. 18 and 20% of injection users; P = 0.11 and 0.02). Only 14% of non-Hispanic black participants met the ADA HbA1c target compared with 34 and 28% in non-Hispanic white and Hispanic participants (adjusted P < 0.001). Among participants with available data, 95 and 86% met ADA and ISPAD HDL targets; 78, 63, 65, and 90% met BP, BMI, LDL, and triglycerides targets.
Figure 1

A: Proportion of participants meeting HbA1c targets (N = 13,226). ADA (black bars): <8.5% for those 1 to younger than 6 years of age, <8.0% for those 6 to younger than 13 years of age, and <7.5% for those 13 to younger than 20 years of age. ISPAD (striped bars): <7.5%. B: Proportion of participants meeting BP target (N = 12,664) <90th percentile for age, sex, and height. C: Proportion of participants meeting BMI target (N = 13,045) <85th percentile for age and sex. BMI percentile was not calculated for those younger than 2 years of age. D: Proportion of participants meeting fasting LDL target (N = 3,010) <100 mg/dL (<2.6 mmol/L). E: Proportion of participants meeting HDL target (N = 8,938). ADA (black bars): >35 mg/dL; ISPAD (striped bars): >1.1 mmol/L. F: Proportion of participants meeting triglycerides target (N = 2,454) <150 mg/dL (<1.7 mmol/L).

A: Proportion of participants meeting HbA1c targets (N = 13,226). ADA (black bars): <8.5% for those 1 to younger than 6 years of age, <8.0% for those 6 to younger than 13 years of age, and <7.5% for those 13 to younger than 20 years of age. ISPAD (striped bars): <7.5%. B: Proportion of participants meeting BP target (N = 12,664) <90th percentile for age, sex, and height. C: Proportion of participants meeting BMI target (N = 13,045) <85th percentile for age and sex. BMI percentile was not calculated for those younger than 2 years of age. D: Proportion of participants meeting fasting LDL target (N = 3,010) <100 mg/dL (<2.6 mmol/L). E: Proportion of participants meeting HDL target (N = 8,938). ADA (black bars): >35 mg/dL; ISPAD (striped bars): >1.1 mmol/L. F: Proportion of participants meeting triglycerides target (N = 2,454) <150 mg/dL (<1.7 mmol/L).

CONCLUSIONS

These data from the T1D Exchange describe how frequently ADA and ISPAD targets are met in the largest reported sample (N = 13,316) of youth with type 1 diabetes in the United States. Only approximately one-third of participants met the age-specific ADA and ISPAD targets for HbA1c. Although the majority of participants did meet BP, lipid, and BMI targets, the frequency of abnormalities for these vascular disease risk factors is concerning (13). Because the clinic registry is not a population-based study, these results may not be representative of all youth with type 1 diabetes. However, participant characteristics were similar to those of patients not enrolled into the registry at the 67 clinics and when compared with the SEARCH for Diabetes in Youth Study (12). Comparisons with DPV German registry are difficult because of differences in target definitions (14). Another limitation is the number of participants missing fasting lipid results and with HbA1c results obtained from point of care. Despite advances in technologies and strategies for care, achieving HbA1c targets remains a significant challenge for the majority of youth in the T1D Exchange registry. Moreover, a large number of youth with diabetes already have additional vascular disease risk factors at a young age. This analysis suggests further transformations to improve pediatric diabetes care are needed to prevent future complications of diabetes.
  14 in total

Review 1.  Management of dyslipidemia in children and adolescents with diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2003-07       Impact factor: 19.112

Review 2.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

3.  Cardiovascular disease (CVD) limbo: how soon and low should we go to prevent CVD in diabetes?

Authors:  David M Maahs
Journal:  Diabetes Technol Ther       Date:  2012-04-03       Impact factor: 6.118

Review 4.  Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association.

Authors:  Janet Silverstein; Georgeanna Klingensmith; Kenneth Copeland; Leslie Plotnick; Francine Kaufman; Lori Laffel; Larry Deeb; Margaret Grey; Barbara Anderson; Lea Ann Holzmeister; Nathaniel Clark
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

5.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

6.  Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study.

Authors:  Beatriz L Rodriguez; Dana Dabelea; Angela D Liese; Wilfred Fujimoto; Beth Waitzfelder; Lenna Liu; Ronny Bell; Jennifer Talton; Beverly M Snively; Ann Kershnar; Elaine Urbina; Stephen Daniels; Giuseppina Imperatore
Journal:  J Pediatr       Date:  2010-04-14       Impact factor: 4.406

7.  The T1D Exchange clinic registry.

Authors:  Roy W Beck; William V Tamborlane; Richard M Bergenstal; Kellee M Miller; Stephanie N DuBose; Callyn A Hall
Journal:  J Clin Endocrinol Metab       Date:  2012-09-20       Impact factor: 5.958

Review 8.  Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment?

Authors:  K Dahl-Jørgensen; J R Larsen; K F Hanssen
Journal:  Diabetologia       Date:  2005-06-22       Impact factor: 10.122

9.  Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes.

Authors:  Ingrid M Libman; Massimo Pietropaolo; Silva A Arslanian; Ronald E LaPorte; Dorothy J Becker
Journal:  Diabetes Care       Date:  2003-10       Impact factor: 19.112

10.  Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

Authors: 
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

View more
  165 in total

1.  Patient perspectives on peer mentoring: type 1 diabetes management in adolescents and young adults.

Authors:  Yang Lu; Elizabeth A Pyatak; Anne L Peters; Jamie R Wood; Michele Kipke; Marisa Cohen; Paola A Sequeira
Journal:  Diabetes Educ       Date:  2014-11-13       Impact factor: 2.140

2.  Challenges in Delivering Smaller Doses of Insulin.

Authors:  Brigitte I Frohnert; G Todd Alonso
Journal:  Diabetes Technol Ther       Date:  2015-09       Impact factor: 6.118

3.  The Future of Glucose Monitoring.

Authors:  Satish K Garg
Journal:  Diabetes Technol Ther       Date:  2016-02       Impact factor: 6.118

4.  Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.

Authors:  Steven J Russell; Mallory A Hillard; Courtney Balliro; Kendra L Magyar; Rajendranath Selagamsetty; Manasi Sinha; Kerry Grennan; Debbie Mondesir; Laya Ekhlaspour; Hui Zheng; Edward R Damiano; Firas H El-Khatib
Journal:  Lancet Diabetes Endocrinol       Date:  2016-02-03       Impact factor: 32.069

5.  Flash Continuous Home Glucose Monitoring to Improve Adherence to Self-Monitoring of Blood Glucose and Self-Efficacy in Adolescents With Type 1 Diabetes.

Authors:  Soo Ting Joyce Lim; Fang Huang; Ngee Lek; Katherine Pereira
Journal:  Clin Diabetes       Date:  2020-04

6.  Undertreatment of hypertension and hypercholesterolaemia in children and adolescents with type 1 diabetes: long-term follow-up on time trends in the occurrence of cardiovascular disease, risk factors and medications use.

Authors:  Fariba Ahmadizar; Patrick Souverein; Anthonius de Boer; Anke H Maitland-van der Zee
Journal:  Br J Clin Pharmacol       Date:  2018-01-25       Impact factor: 4.335

7.  Persistently high glucose levels in young children with type 1 diabetes.

Authors:  M Tansey; R Beck; K Ruedy; W Tamborlane; P Cheng; C Kollman; L Fox; S Weinzimer; N Mauras; N H White; E Tsalikian
Journal:  Pediatr Diabetes       Date:  2014-12-11       Impact factor: 4.866

Review 8.  Psychosocial factors in medication adherence and diabetes self-management: Implications for research and practice.

Authors:  Jeffrey S Gonzalez; Molly L Tanenbaum; Persis V Commissariat
Journal:  Am Psychol       Date:  2016-10

9.  Youth-Perceived Burden of Type 1 Diabetes: Problem Areas in Diabetes Survey-Pediatric Version (PAID-Peds).

Authors:  Jessica T Markowitz; Lisa K Volkening; Deborah A Butler; Lori M B Laffel
Journal:  J Diabetes Sci Technol       Date:  2015-04-24

10.  Clinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study.

Authors:  Eda Cengiz; Peiyao Cheng; Katrina J Ruedy; Craig Kollman; William V Tamborlane; Georgeanna J Klingensmith; Robin L Gal; Janet Silverstein; Joyce Lee; Maria J Redondo; Roy W Beck
Journal:  Pediatr Diabetes       Date:  2016-10-19       Impact factor: 4.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.